ATEZOLIZUMAB MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Atezolizumab Market, By Drug Class (PD-L1 Inhibitors, PD-1 Inhibitors, CTLA-4 Inhibitors, Immunomodulators, and Others), By Indication (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin’s Lymphoma, Head and Neck Cancer, and Others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments

New product launches

In March 2022, Roche, Swiss bases multinational healthcare company, launched a new subcutaneous formulation of Tecentriq for treating non-small cell lung cancer. The formulation provides flexibility and reduces administration time.
In June 2021, BeiGene, global biotechnology company that is discovering and developing innovative oncology treatments announced the approval of its PD-1 inhibitor tislelizumab in China for treating previously treated locally advanced or metastatic esophageal squamous cell carcinoma. This expanded tislelizumab’s applicability.
In April 2021, Bristol Myers Squibb, U.S based multinational pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy for treating metastatic or recurrent non-small cell lung cancer. This combination regime improved overall survival.

Acquisition and partnerships

In October 2022, Seagen, U.S. based Biotechnology Company, and RemeGen, global biopharmaceutical company, focusing on the discovery, development and commercialization of novel biologics, announced a collaboration agreement to develop disitamab vedotin, an antibody-drug conjugate, in Asia Pacific and other regions.
In December 2021, Novartis, U.S. based global Pharmaceutical Company, acquired Arctos Medical, a spin-off company from the University of Bern and has developed a revolutionary gene therapy, obtaining its rights to an early-stage STING (STimulator of INterferon Gene) agonist program. This enhanced Novartis’ immuno-oncology pipeline.
In April 2020, Pfizer, Global Pharmaceutical and Biotechnology Company, completed the acquisition of Array Biopharma, a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs, strengthening its portfolio of targeted cancer medicines paired with immuno-oncology drugs.